401 related articles for article (PubMed ID: 31511015)
1. Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation.
Vu TN; Chen X; Foda HD; Smaldone GC; Hasaneen NA
Respir Res; 2019 Sep; 20(1):206. PubMed ID: 31511015
[TBL] [Abstract][Full Text] [Related]
2. Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis.
Togami K; Kanehira Y; Tada H
Biol Pharm Bull; 2013; 36(10):1525-7. PubMed ID: 24088250
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1.
Jin J; Togo S; Kadoya K; Tulafu M; Namba Y; Iwai M; Watanabe J; Nagahama K; Okabe T; Hidayat M; Kodama Y; Kitamura H; Ogura T; Kitamura N; Ikeo K; Sasaki S; Tominaga S; Takahashi K
Respir Res; 2019 Jun; 20(1):119. PubMed ID: 31185973
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Epstein Shochet G; Wollin L; Shitrit D
Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
6. The mechanism of Shenlong Jianji treatment of idiopathic pulmonary fibrosis inhibits fibroblast-to-myofibroblast transformation via the TGF-β1/smads signaling pathway.
Pan J; Li Y; Wu X; Pan X; Liu C; Zhang H; Wang L; Jiang X; Wang J; Zang N; Pang L; Lv X
J Ethnopharmacol; 2024 Mar; 322():117507. PubMed ID: 38122910
[TBL] [Abstract][Full Text] [Related]
7. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy.
Kurita Y; Araya J; Minagawa S; Hara H; Ichikawa A; Saito N; Kadota T; Tsubouchi K; Sato N; Yoshida M; Kobayashi K; Ito S; Fujita Y; Utsumi H; Yanagisawa H; Hashimoto M; Wakui H; Yoshii Y; Ishikawa T; Numata T; Kaneko Y; Asano H; Yamashita M; Odaka M; Morikawa T; Nakayama K; Kuwano K
Respir Res; 2017 Jun; 18(1):114. PubMed ID: 28577568
[TBL] [Abstract][Full Text] [Related]
8. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3).
Wu C; Lin H; Zhang X
Int Immunopharmacol; 2019 Sep; 74():105700. PubMed ID: 31228816
[TBL] [Abstract][Full Text] [Related]
10. Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo.
Ma Z; Zhao C; Chen Q; Yu C; Zhang H; Zhang Z; Huang W; Shen Z
Pulm Pharmacol Ther; 2018 Dec; 53():100-106. PubMed ID: 30394340
[TBL] [Abstract][Full Text] [Related]
11. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.
Conte E; Gili E; Fagone E; Fruciano M; Iemmolo M; Vancheri C
Eur J Pharm Sci; 2014 Jul; 58():13-9. PubMed ID: 24613900
[TBL] [Abstract][Full Text] [Related]
12. Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models.
Yu W; Guo F; Song X
Pharm Biol; 2017 Dec; 55(1):450-455. PubMed ID: 27937011
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of pirfenidone-NSAIDs conjugates for the treatment of idiopathic pulmonary fibrosis.
Lu X; Zhu C; Gao Y; Yu Z; Yan Q; Liu Y; Luo M; Shi X
Bioorg Chem; 2024 Feb; 143():107018. PubMed ID: 38071874
[TBL] [Abstract][Full Text] [Related]
14. Autophagy and the unfolded protein response promote profibrotic effects of TGF-β
Ghavami S; Yeganeh B; Zeki AA; Shojaei S; Kenyon NJ; Ott S; Samali A; Patterson J; Alizadeh J; Moghadam AR; Dixon IMC; Unruh H; Knight DA; Post M; Klonisch T; Halayko AJ
Am J Physiol Lung Cell Mol Physiol; 2018 Mar; 314(3):L493-L504. PubMed ID: 29074489
[TBL] [Abstract][Full Text] [Related]
15. Effect of Pirfenidone on TGF-β1-Induced Myofibroblast Differentiation and Extracellular Matrix Homeostasis of Human Orbital Fibroblasts in Graves' Ophthalmopathy.
Wu SB; Hou TY; Kau HC; Tsai CC
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680057
[TBL] [Abstract][Full Text] [Related]
16. Curdione ameliorates bleomycin-induced pulmonary fibrosis by repressing TGF-β-induced fibroblast to myofibroblast differentiation.
Liu P; Miao K; Zhang L; Mou Y; Xu Y; Xiong W; Yu J; Wang Y
Respir Res; 2020 Feb; 21(1):58. PubMed ID: 32075634
[TBL] [Abstract][Full Text] [Related]
17. Andrographolide ameliorates bleomycin-induced pulmonary fibrosis by suppressing cell proliferation and myofibroblast differentiation of fibroblasts via the TGF-β1-mediated Smad-dependent and -independent pathways.
Li J; Feng M; Sun R; Li Z; Hu L; Peng G; Xu X; Wang W; Cui F; Yue W; He J; Liu J
Toxicol Lett; 2020 Mar; 321():103-113. PubMed ID: 31706003
[TBL] [Abstract][Full Text] [Related]
18. Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation.
Lambers C; Roth M; Jaksch P; Muraközy G; Tamm M; Klepetko W; Ghanim B; Zhao F
Sci Rep; 2018 Jan; 8(1):1087. PubMed ID: 29348469
[TBL] [Abstract][Full Text] [Related]
19. Pirfenidone inhibits the proliferation of fibroblasts from patients with active Crohn's disease.
Kadir SI; Wenzel Kragstrup T; Dige A; Kok Jensen S; Dahlerup JF; Kelsen J
Scand J Gastroenterol; 2016 Nov; 51(11):1321-5. PubMed ID: 27181436
[TBL] [Abstract][Full Text] [Related]
20. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts.
Nakayama S; Mukae H; Sakamoto N; Kakugawa T; Yoshioka S; Soda H; Oku H; Urata Y; Kondo T; Kubota H; Nagata K; Kohno S
Life Sci; 2008 Jan; 82(3-4):210-7. PubMed ID: 18093617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
